Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Defining response and non-response to treatment in patients with overactive bladder: a systematic review.

Goldman HB, Wyndaele JJ, Kaplan SA, Wang JT, Ntanios F.

Curr Med Res Opin. 2014 Mar;30(3):509-26. doi: 10.1185/03007995.2013.860021. Epub 2013 Nov 25. Review.

PMID:
24164097
2.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Review.

PMID:
22161392
3.

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.

Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD.

BMC Urol. 2009 Nov 20;9:18. doi: 10.1186/1471-2490-9-18. Review.

4.

Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.

Chapple C, Oelke M, Kaplan SA, Scholfield D, Arumi D, Wagg AS.

Curr Med Res Opin. 2015 Jun;31(6):1201-43. doi: 10.1185/03007995.2015.1032917. Epub 2015 Apr 23. Review.

PMID:
25798911
5.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.

BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.

6.

Economic burden of urgency urinary incontinence in the United States: a systematic review.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I.

J Manag Care Pharm. 2014 Feb;20(2):130-40. Review.

7.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie J, Wilson DI, Herbison GP, Wilson D.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493. Review. Update in: Cochrane Database Syst Rev. 2011;(12):CD005493.

PMID:
17636801
8.

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.

Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18. Review.

PMID:
24275310
9.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
10.

The responsiveness of the OAB-q among OAB patient subgroups.

Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T.

Neurourol Urodyn. 2007;26(2):196-203.

PMID:
17016794
11.

Redefining response in overactive bladder syndrome.

Payne CK, Kelleher C.

BJU Int. 2007 Jan;99(1):101-6. Review.

12.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

13.

Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.

Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC.

Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11. Review.

PMID:
24127366
14.

[Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].

Henriet B, Roumeguère T.

Rev Med Brux. 2015 Jan-Feb;36(1):29-37. Review. French.

PMID:
25856969
15.

Understanding the elements of overactive bladder: questions raised by the EPIC study.

Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K; EPIC Study Group.

BJU Int. 2008 Jun;101(11):1381-7. doi: 10.1111/j.1464-410X.2008.07573.x. Epub 2008 Mar 10.

16.

Botulinum-A Toxin's efficacy in the treatment of idiopathic overactive bladder.

Moga MA, Banciu S, Dimienescu O, Bigiu NF, Scarneciu I.

J Pak Med Assoc. 2015 Jan;65(1):76-80. Review.

PMID:
25831681
17.

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.

Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z.

BJU Int. 2012 Jun;109(12):1831-40. doi: 10.1111/j.1464-410X.2011.10624.x. Epub 2011 Oct 3.

18.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
19.

Solifenacin succinate for the treatment of symptoms of overactive bladder.

Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R.

Clin Ther. 2006 Sep;28(9):1247-72. Review.

PMID:
17062299
20.

An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.

Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C.

Eur Urol. 2014 May;65(5):981-90. doi: 10.1016/j.eururo.2013.10.033. Epub 2013 Nov 1. Review.

PMID:
24239446

Supplemental Content

Support Center